Chromosomes entangled with DNA ribbons, representing genetic rearrangements in blood cancer.

Decoding the Genetic Puzzle: How Chromosome Rearrangements Impact Blood Cancer

Author's portrait.
Soraya Malik in Health & Wellness August 2025 • 4 min read.

"Unraveling the link between t(3;8)(q26.2;q24) translocation and therapy-related myeloid neoplasms for better prognosis."


In the complex world of genetics, chromosomal rearrangements can act as significant drivers of disease, particularly in cancer. Among these, the translocation t(3;8)(q26.2;q24) stands out as a rare yet critical abnormality associated with myeloid neoplasms, a group of cancers affecting the blood and bone marrow. This translocation involves the exchange of genetic material between chromosomes 3 and 8 at specific locations, leading to the disruption and rearrangement of key genes.

A recent study has shed light on the clinical and molecular characteristics of patients with myeloid neoplasms harboring the t(3;8)(q26.2;q24) translocation. The research, which analyzed data from 20 patients, reveals a strong association between this genetic anomaly and therapy-related myeloid neoplasms (t-MN), cancers that arise as a consequence of previous chemotherapy or radiation treatments. The translocation often results in the rearrangement of the MECOM and MYC genes, both of which play crucial roles in cell growth and development.

Understanding the implications of t(3;8)(q26.2;q24) is vital for improving the diagnosis, prognosis, and treatment of affected individuals. By delving into the genetic and clinical features of this rare translocation, researchers aim to pave the way for more targeted and effective therapies, ultimately improving the outcomes for patients with these aggressive blood cancers.

Unveiling the Role of MECOM and MYC Rearrangements

Chromosomes entangled with DNA ribbons, representing genetic rearrangements in blood cancer.

The t(3;8)(q26.2;q24) translocation is particularly noteworthy due to its impact on two important genes: MECOM (MDS1 and EVI1 complex locus) and MYC. MECOM, located on chromosome 3, plays a crucial role in hematopoiesis, the formation of blood cells. MYC, situated on chromosome 8, is a well-known oncogene involved in cell growth, proliferation, and differentiation. When the translocation occurs, these genes can become dysregulated, leading to abnormal cell behavior and cancer development.

In the study, fluorescence in situ hybridization (FISH) analysis revealed MECOM rearrangement in 18 out of 19 patients and MYC rearrangement in 16 out of 18 patients. This high frequency of rearrangement underscores the significance of these genetic events in the pathogenesis of myeloid neoplasms associated with t(3;8)(q26.2;q24). Furthermore, the researchers found that Myc protein expression was consistently present in the cases assessed, indicating that the translocation leads to increased activity of this oncogene.

The key findings regarding MECOM and MYC include:
  • MECOM rearrangement was detected in 95% of patients tested.
  • MYC rearrangement was found in 89% of patients tested.
  • Myc protein expression was consistently present in assessed cases.
These findings suggest that the t(3;8)(q26.2;q24) translocation disrupts the normal regulation of MECOM and MYC, leading to their overexpression or aberrant activity. This, in turn, contributes to the uncontrolled proliferation and impaired differentiation of myeloid cells, ultimately driving the development of myeloid neoplasms.

Implications for Prognosis and Treatment

The study's findings have important implications for the prognosis and treatment of patients with myeloid neoplasms associated with t(3;8)(q26.2;q24). The researchers observed that patients with this translocation often have a dismal outcome, with a median overall survival of only six months. This highlights the aggressive nature of these cancers and the need for more effective treatment strategies. Understanding the molecular mechanisms underlying the pathogenesis of these neoplasms may lead to the development of targeted therapies that specifically inhibit the activity of MECOM or MYC, or that counteract the downstream effects of their dysregulation. Further research is needed to explore these possibilities and to identify novel therapeutic targets for this challenging group of blood cancers.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

Everything You Need To Know

1

What is the t(3;8)(q26.2;q24) translocation and how does it relate to blood cancer?

The translocation t(3;8)(q26.2;q24) involves the exchange of genetic material between chromosomes 3 and 8. This rearrangement can disrupt the normal function of key genes, notably MECOM and MYC. MECOM, located on chromosome 3, is vital for blood cell formation, while MYC, on chromosome 8, regulates cell growth and proliferation. This disruption contributes to the development of myeloid neoplasms.

2

What role does the MECOM gene play in myeloid neoplasms associated with the t(3;8)(q26.2;q24) translocation?

MECOM (MDS1 and EVI1 complex locus) is located on chromosome 3 and plays a crucial role in hematopoiesis, the formation of blood cells. When the t(3;8)(q26.2;q24) translocation occurs, MECOM can become dysregulated, leading to abnormal blood cell development and contributing to myeloid neoplasms. Its rearrangement was detected in 95% of patients tested, underscoring its significance in the pathogenesis of myeloid neoplasms associated with the translocation.

3

How is the MYC gene affected by the t(3;8)(q26.2;q24) translocation, and what are the implications?

MYC is an oncogene located on chromosome 8 involved in cell growth, proliferation, and differentiation. In the context of the t(3;8)(q26.2;q24) translocation, MYC can become overexpressed or aberrantly activated, leading to uncontrolled proliferation and impaired differentiation of myeloid cells. Research found MYC rearrangement in 89% of patients tested and consistently present Myc protein expression in assessed cases, which further underscores its role.

4

What impact does the t(3;8)(q26.2;q24) translocation have on the prognosis and treatment of myeloid neoplasms?

The t(3;8)(q26.2;q24) translocation is associated with a poor prognosis in patients with myeloid neoplasms, with a median overall survival of only six months. This outcome underscores the aggressive nature of these cancers and highlights the need for the development of more effective treatment strategies. Further research into the molecular mechanisms may lead to targeted therapies that inhibit MECOM or MYC activity.

5

How is Fluorescence in situ hybridization (FISH) used in the context of t(3;8)(q26.2;q24) translocation research, and what other techniques could complement its findings?

Fluorescence in situ hybridization (FISH) is a molecular cytogenetic technique used to detect and visualize specific DNA sequences on chromosomes. In the study, FISH analysis was used to identify MECOM and MYC rearrangements in patients with myeloid neoplasms harboring the t(3;8)(q26.2;q24) translocation. The results showed a high frequency of MECOM and MYC rearrangements, confirming the significance of these genetic events in the development of these cancers. While FISH is valuable, other techniques like karyotyping and next-generation sequencing can provide a broader view of chromosomal abnormalities and gene mutations.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.